Embrex Inc. (NASDAQ:EMBX) announced Wednesday that theU.S. Department of Agriculture approved field trials for apoultry Infectious Bursal disease vaccine complex containingEmbrex's Viral Neutralizing Factor, a biological delivery systemthat delays release of the vaccine until it is needed by the bird.

The field trials will be conducted by Sanofi Animal Health,which has been granted exclusive rights by Embrex of ResearchTriangle Park, N.C., to market the complex upon regulatoryapproval in the U.S., Latin America and Asia.

(c) 1997 American Health Consultants. All rights reserved.

No Comments